3//SEC Filing
Gurnet Holding Co 3
Accession 0001104659-18-063119
CIK 0001594337other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 6:01 AM ET
Size
38.6 KB
Accession
0001104659-18-063119
Insider Transaction Report
Form 3
Gurnet Holding Co
10% Owner
Holdings
- 0(indirect: N/A)
Common Stock, par value $0.001 per share
Gurnet Point, L.P.
10% Owner
Holdings
- 0(indirect: N/A)
Common Stock, par value $0.001 per share
Gurnet Merger Sub, Inc.
10% Owner
Holdings
- 0(indirect: N/A)
Common Stock, par value $0.001 per share
Footnotes (4)
- [F1]Gurnet Holding Company ("Parent") and its direct wholly owned subsidiary, Gurnet Merger Sub, Inc. ("Merger Sub"), entered into an Agreement and Plan of Merger, dated as of October 11, 2018 (the "Merger Agreement"), with Corium International, Inc. ("Corium"), pursuant to which Merger Sub will commence a tender offer (the "Offer") to purchase all of the issued and outstanding shares of Common Stock, par value $0.001 per share, of Corium (the "Shares"), at a purchase price of $12.50 per Share in cash, plus one non-transferable contingent value right for each share, which represents the contractual right to receive $0.50 per Share following approval by the FDA of the New Drug Application for Corplex Donepezil, as described in and under the terms of the Contingent Value Rights Agreement (as described in the Merger Agreement), without interest. (Continued in Footnote 2)
- [F2]Upon successful completion of the Offer, and subject to the terms and conditions of the Merger Agreement, Merger Sub will be merged with and into Corium with Corium surviving the Merger and becoming a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger Agreement, Parent and Merger Sub entered into a tender and support agreement, dated as of October 11, 2018 (the "Tender and Support Agreement"), with Essex Woodlands Health Ventures Fund VII, L.P., who agreed, subject to certain limited specified exceptions, to tender into the Offer, and not withdraw, all Shares owned of record or beneficially owned or acquired by them after such date (the "Subject Shares"), to vote the Subject Shares in favor of the Merger and vote against alternative acquisition proposals to the Merger and to refrain from disposing of the Subject Shares. (Continued in Footnote 3)
- [F3]As of the date hereof, the Subject Shares include 9,353,304 Shares beneficially owned by Essex Woodlands Health Ventures Fund VII, L.P.
- [F4]As Merger Sub is a direct wholly-owned subsidiary of Parent, and because Parent and Merger Sub executed the Tender and Support Agreement, and as a result of Parent being a direct wholly-owned subsidiary Gurnet Point L.P. ("Gurnet Point") and Waypoint International GP LLC being the general partner of Gurnet Point ("Waypoint"), each of Parent, Merger Sub, Gurnet Point and Waypoint (collectively, the "Reporting Persons") may be deemed to have acquired beneficial ownership over the Subject Shares for the purpose of determining its status as a ten percent holder thereof. However, as none of the Reporting Persons have any pecuniary interest in the Subject Shares, beneficial ownership over the Subject Shares is expressly disclaimed for reporting purposes.
Issuer
Corium International, Inc.
CIK 0001594337
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001756450
Filing Metadata
- Form type
- 3
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 6:01 AM ET
- Size
- 38.6 KB